<DOC>
	<DOCNO>NCT01320228</DOCNO>
	<brief_summary>The objective Orlifat trial investigate dietary fibre linseeds dairy calcium ( Capolac ® ) may reduce gastrointestinal side effect relate increased fecal fat content , induced treatment Alli® ( orlistat ) . Secondly , effect food intake , anthropometry , Quality Life cardiovascular risk marker evaluate . The trial design randomise 2 x 2 factorial 13-weeks parallel intervention , 72 obese participant randomise supplementation flaxseed fibres and/or dairy calcium concentrate ( Capolac ) addition treatment Alli ® : 1 . Alli® ( 60 mg t.i.d ) plus placebo ( rice flour ) 2 . Alli® plus 5 g flaxseed fiber 3 . Alli® plus 1200 mg Ca Capolac 4 . Alli® plus 5 g flaxseed fiber 1200 mg Ca Capolac</brief_summary>
	<brief_title>Effect Dietary Components Gastrointestinal Side Effects Induced Orlistat , Lipase Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Orlistat</mesh_term>
	<criteria>2060 year age men woman BMI 3040 kg/m2 Dairy allergy and/or intolerance , allergy Orlistat Infectious metabolic disease Gastrointestinal disease ( previous current ) Troubles swallow tablet capsule Dietary supplement use trial 1 month prior trial Postmenopausal ( selfreported ) Pregnancy lactation Treatment oral anticoagulation medication , ciclosporin , levothyroxin , antiepileptika , acarbose amiodaron Prescription medication consider individual basis screen visit accord SOP Dieting change diet within 3 month Participation trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Obesity</keyword>
	<keyword>orlistat</keyword>
	<keyword>fat excretion</keyword>
	<keyword>fiber</keyword>
	<keyword>dairy calcium</keyword>
</DOC>